1. Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):127-31. doi: 
10.3779/j.issn.1009-3419.2011.02.04.

[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum 
for advanced pulmonary adenocarcinoma].

[Article in Chinese]

Han R(1), Zhong W, Zhao J, Zhang L, Xia Y, Wang H, Li L, Wang M.

Author information:
(1)Department of Respiratory Disease, Peking Union Medical College Hospital, 
Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 
100730, China.

BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) with mutations in 
the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLC, 
which is particularly responsive to EGFR tyrosine kinase inhibitors (TKIs). The 
aim of this study is to detect EGFR mutations in paired serum of pre- and 
post-chemotherapy from advanced pulmonary adenocarcinoma patients to evaluate 
impact of chemotherapy on EGFR mutation status.
METHODS: Magnetic beads were used for DNA extraction from paired serum of pre- 
and post-chemotherapy of 33 advanced pulmonary adenocarcinoma patients. The EGFR 
exon 19 and 21 were amplified by mutant-enriched nested PCR and analyzed by 
direct sequencing.
RESULTS: EGFR mutations were detected in 39.4% (13/33) and 54.5% (18/33) serum 
samples of pre- and postchemotherapy, respectively. The EGFR mutation status was 
consistent in 54.5% (18/33) patients. Among 15 discordant cases, 10 changed from 
pre-chemo wild-type to post-chemo mutant-type status, while 5 from pre-chemo 
mutant-type to post-chemo wild-type status.
CONCLUSIONS: Chemotherapy may have influence on serum EGFR mutation status in 
advanced adenocarcinoma patients.

背景与目的: 存在表皮生长因子受体（epidermal growth factor receptor, EGFR）基因突变的非小细胞肺癌（non-small 
cell lung cancer, NSCLC）作为NSCLC的一个特殊亚群，对于表皮生长因子酪氨酸激酶抑制剂（epidermal growth factor 
receptor tyrosine kinase inhibitor, 
EGFR-TKI）的治疗显示出良好的疗效。本研究旨在检测晚期肺腺癌患者化疗前后血清EGFR基因外显子19和外显子21的突变状态，并分析化疗是否对EGFR基因突变状态产生影响。
方法: 
磁珠法提取血清游离DNA后，使用酶切富集巢式PCR分别对血清游离DNA中EGFR外显子19和外显子21进行特异性扩增，应用直接测序法对EGFR基因突变状态进行检测。
结果: 
33例肺腺癌患者化疗前EGFR基因突变率为39.4%（13/33），化疗后为54.5%（18/33），化疗前后EGFR基因突变状态的一致率为54.5%（18/33）；在不一致的15例患者中，10例由化疗前EGFR基因突变阴性变为阳性，5例由化疗前阳性变为阴性。
结论: 化疗可能导致血清EGFR基因突变状态的改变。

DOI: 10.3779/j.issn.1009-3419.2011.02.04
PMCID: PMC5999769
PMID: 21342642 [Indexed for MEDLINE]